TuHURA Biosciences (NASDAQ:HURA) Releases Earnings Results, Beats Expectations By $0.02 EPS

TuHURA Biosciences (NASDAQ:HURA) issued its earnings results on Tuesday. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02, FiscalAI reports.

TuHURA Biosciences Price Performance

Shares of NASDAQ HURA traded up $0.06 during midday trading on Tuesday, hitting $1.79. 265,409 shares of the company’s stock were exchanged, compared to its average volume of 806,305. TuHURA Biosciences has a twelve month low of $0.41 and a twelve month high of $4.44. The firm has a market cap of $108.69 million, a P/E ratio of -3.58 and a beta of -0.30. The stock’s 50 day moving average price is $1.34 and its 200-day moving average price is $1.64.

Institutional Trading of TuHURA Biosciences

Several hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in TuHURA Biosciences during the 3rd quarter worth $26,000. JPMorgan Chase & Co. bought a new stake in shares of TuHURA Biosciences during the second quarter valued at about $27,000. Invesco Ltd. bought a new stake in shares of TuHURA Biosciences during the second quarter valued at about $30,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in TuHURA Biosciences in the second quarter worth about $31,000. Finally, Bank of America Corp DE acquired a new stake in TuHURA Biosciences in the fourth quarter worth about $59,000. Institutional investors own 0.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on HURA. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of TuHURA Biosciences in a research report on Tuesday, February 3rd. Wall Street Zen upgraded TuHURA Biosciences from a “sell” rating to a “hold” rating in a research note on Monday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $9.00.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.